Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)

NCT01774630 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG: Nilotinib

Sponsor

University Hospital, Bordeaux